One Case of Dermatitis Medicamentosa in a Paediatric Epilepsy Patient Caused by Lacosamide Oral Solution

doi:10.19803/j.1672-8629.20240461

Abstract

Abstract: Objective To analyze dermatitis medicamentosa caused by lacosamide oral solution so as to provide references for safe and rational drug use. Methods A retrospective study was conducted on a pediatric epilepsy patient who experienced dermatitis medicamentosa after oral administration of lacosamide oral solution. The potential cause of the adverse drug reaction and overall safety were explored. Results The Naranjo scale suggested that lacosamide was likely associated with the adverse drug reaction. Following discontinuation of lacosamide oral solution and symptomatic treatment, the symptoms of dermatitis medicamentosa disappeared gradually. Conclusion It is recommended that lacosamide be administered at a small dose that should be increased gradually in children under 4 years old. The blood concentration should be monitored to ensure the safety.

Key words: Lacosamide, Oral Solution, Children, Epilepsy, Dermatitis Medicamentosa, Adverse Drug Reaction, Safety, Efficacy

CLC Number:

LUO Wen, WU Jing, HE Dake, YANG Rui. One Case of Dermatitis Medicamentosa in a Paediatric Epilepsy Patient Caused by Lacosamide Oral Solution[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 452-455.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240461

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I4/452

References

[1] CASCIATO S, QUARATO PP, GIALLUISI A, et al.Lacosamide as First Addon or Conversion Mono-Therapy: a Retrospective Real-Life Study[J]. Epilepsy Behav, 2021, 122: 108-128.
[2] ABOU-KHALIL BW.Update on Antiseizure Medications 2022[J]. Continuum (Minneap Minn), 2022, 28(2): 500-535.
[3] ZHOU TT, ZHANG Y, WANG L.Epidemiological Analysis of Lacos-amide-Related Adverse Drug Reactions Based on OpenFDA[J]. Anti-Infection Pharmacy(抗感染药学), 2024, 21(6): 577-581.
[4] BABAR RK, BRESNAHAN R, GILLESLIE CS, et al. Lacosamide Add-on Therapy for Focal Epilepsy[J]. Cochrane Database Syst Rev, 2021, 5(5): CD008841.
[5] FONG SL, UTIDJIAN L, KAUR M, et al.Safety of Intravenous Laco-samide in Hospitalized Children and Neonates[J]. Epilepsia, 2023, 64(9):2297-2309.
[6] WELSH SS, LIN N, TOPJIAN AA, et al.Safety of Intravenous Lacosa-mide in Critically Ill Children[J]. Seizure, 2017, 52: 76-80.
[7] GAFFNEY RG, TARAZI M, WERTH VP.Drug-Induced Dermato-myositis after Lacosamide: A Case Report[J]. JAAD Case Rep, 2018, 4(6): 584-585.
[8] KARDAUN SH, VOS BJ, CHANDRAN NS.Stevens Johnson Syndrome/Toxic Epidermal Necrolysis-Overlap, Induced by Lacosamide[J]. Eur J Dermatol, 2016, 26(2): 185-186.
[9] FONG MK, SHENG B.DRESS Syndrome: a Case of Cross-Reactivity with Lacosamide?[J]. Epilepsia Open, 2017, 2(2): 273-275.
[10] KOUBEISSI M Z, VISMER M, EHRLICH A.Lacosamide-Induced Rash[J]. Epileptic Disord, 2014, 16(3): 380-383.
[11] YIN YQ, ZHOU ZJ, LI CM, et al.Mining and Analysis of Adverse Drug Event Signals of Lacosamide[J]. China Pharmacy(中国药房), 2024, 35(10): 1249-1253.
[12] SI HC, DAI YY.Clinical Efficacy of Lacosamid Additive in Treatment of Focal Epilepsy in Children[J]. Journal of Medical Research(医学研究杂志), 2022, 51(9): 159-162.
[13] GUO M, ZHOU HL, XU L.Efficacy of Valproic Acid Combined with Lacosalamine in the Treatment of Children with Partial Seizure Epilepsy[J]. Journal of Clinical and Experimental Medicine(临床和实验医学杂志), 2023, 22(15): 1635-1639.
[14] ZHAO Y, LING Y.Study on the Efficacy of Lacoxamide Combined with Sodium Valproate in the Treatment of Refractory Epilepsy[J]. Chinese Journal of Drug Abuse Prevention and Treatment(中国药物滥用防治杂志), 2024, 30(1): 10-14.
[15] Center for Drug Evaluation. NMPA. Guidelines for Assessing the Relationship Between Adverse Events in Clinical Trials of Drugs[EB/OL]. (2024-06-14)[2024-07-14]. https://www.cde.org.cn.
[16] NARANIO CA, BUSTO U, SELLERS, et al. A Method for Estimating the Probability of Adverse Drug Reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[17] US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5[J]. Actas Dermo-Sifiliográficas (English Edition), 2021, 112(1): 90-92.
[18] VERROTTI A, LOIACONO G, PIZZOLORUSSO A, et al.Lacosamide in Pediatric and Adult Patients: Comparison of Efficacy and Safety[J]. Seizure, 2013, 22(3): 210-216.
[19] HMAIMESS G, SABBAGH S, DIRANI M, et al.Efficacy and Tolera-bility of Treatment with Lacosamide in Children: Postmarketing Experience from the Middle East[J]. Seizure, 2020, 79: 75-79.
[20] XU C, TANG JH, XIAO X, et al.Clinical Analysis of Lacosamide in the Treatment of Infantile Focal Epilepsy[J]. Journal of Epilepsy(癫痫杂志), 2023, 9(1): 22-25.
[21] CASAS-FERNANDEZ C, MARTINE-BERMEJO A, RUFO-CAMPOS M, et al.Efficacy and Tolerability of Lacosamide in the Concomitant Treatment of 130 Patients under 16 Years of Age with Refractory Epilepsy: a Prospective, Open-Label, Observational, Multicenter Study in Spain[J]. Drugs in R&D, 2012, 12(4): 187-197.
[22] MCGINNIS E, KESSLER SK.Lacosamide Use in Children with Epilepsy: Retention Rate and Effect of Concomitant Sodium Channel Blockers in a Large Cohort[J]. Epilepsia, 2016, 57(9): 1416-1425.
[23] China Association Against Epilepsy. Clinical Practice Guidelines:Epilepsy(临床诊疗指南:癫痫病分册)[M]. Beijing: People's Medical Publishing House, 2023.
[24] YU J, PALATI R, ZHAO T, et al.Correlation of the Efficacy, Safety and Plasma Concen-tration of Lacosamide in the Treatment of Children with Epilepsy under 4 Years of Age[J]. Chinese Journal of Pharmacov-igilance(中国药物警戒), 2024, 21(5): 559-562, 566.
[25] LI Y, GUO HL, ZHAO YT, et al.An Updated Review on Therapeutic Drug Monitoring of Lacosamide for Children with Epilepsy[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2023, 58(19): 1731-1735.